Table 1.

P2 receptor drugs and signaling inhibitors: abbreviations and doses used in this study

Drug	Dose
Adenosine triphosphate (ATP, P2 purinergic receptor agonist)	0.5–1 mM
Adenosine-5′-(γ-thio)-triphosphate (ATPγS. P2 purinergic receptor agonist, a nonhydrolyzable analog of ATP)	100–500 µM
Adenosine 5′-O-2-thiodiphosphate (ADP-β-S, P2 receptor agonist)	50–100 µM
2-Methylthioadenosine triphosphate (2-MT ATP, P2Y receptor agonist)	10–20 µM
2′(3′)-O-(4-Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP, selective P2X7 receptor agonist)	10–50 µM
Pyridoxalphosphate-6-azophenyl-2′,5′-disulfonic acid (Iso-PPADS, P2X-purinoceptor antagonist)	10–50 µM
N-cyano-N′′-[(1S)-1-phenylethyl]-N′-5-quinolinyl-guanidine (A804598, selective P2X7 antagonist)	10–25 µM
Bisindolylmaleimide (BIS, selective protein kinase C inhibitor)	50–200 nM
2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one (PD98058, MEK1 inhibitor to block ERK MAPK signaling)	20–50 µM
2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002, PI3 kinase inhibitor to inhibit AKT signaling)	5–10 µM